The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues, while a US biopharma group is calling for industries to boycott all non-food and medical trade with Russia.

The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues while a US biopharma group is calling for industry to boycott all non-food and medical trade with Russia.

The big pharma has a gene therapy R&D site in New York from its Prevail Therapeutics buy; the RNA-focused Boston site also will conduct drug delivery research benefitting programs at both locations.

The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.